Intralipid 10% Injection (Refined Soybean Oil)

Adult administration

Generally, administer up to 2 g per day per kg of body weight (for 10% solution: 20 mL, for 20% solution: 10 mL). Infuse over 3 hours or more as an intravenous drip. On the first day, for the initial injection, administer no more than 1 g per kg of body weight. Infusion should be adjusted according to the patient's physiological metabolic status and the requirements for essential fatty acids and calories.

Caution is required when administering this drug to premature and low-birth-weight infants. They have a lower capacity to metabolize fats, which may result in elevated levels of free fatty acids in the blood. When administered intravenously to premature infants with severe respiratory diseases, there is a risk of fat accumulation in the pulmonary vessels, which requires caution. This drug should not be used in patients with thrombosis, severe liver disease, severe blood coagulation disorders, hyperlipidemia, diabetes with ketoacidosis, acute shock, electrolyte imbalances, unstable metabolic state, and patients with Chylothorax. Additionally, it should not be administered to individuals with allergic reactions to phospholipids or the ingredients of this medication, as well as to patients sensitized to egg, soybean, and peanut proteins. This medication should be used cautiously in patients with liver dysfunction, blood coagulation disorders, respiratory distress, premature infants, severe bacterial sepsis, pregnant women, brain disorders, acute pancreatitis, comatose states, and lipid metabolism disorders. During the use of this medication, side effects such as phlebitis, vascular pain, bleeding tendency, thrombosis, liver dysfunction, hypotension, tachycardia, difficulty breathing, nausea, vomiting, diarrhea, and other symptoms may occur, and immediate reporting and appropriate measures should be taken if symptoms appear. In cases of excessive fat administration, hyperlipidemia, fever, fat deposits, blood coagulation abnormalities, and in severe cases, coma can occur, so caution is required. Regular monitoring of liver function, blood lipid levels, blood tests, and coagulation ability is necessary during long-term use. This medication contains soybean oil and phospholipids and may rarely cause allergic reactions, and there is also a risk of cross-reactivity with soy and peanuts. It may decrease the effect of warfarin and affect lipid breakdown in conjunction with heparin, so consultation with a doctor is advised. Particularly when administered to neonates and premature infants, the infusion should be slow due to their reduced ability to handle fat, and the blood lipid levels should be closely monitored. In neonates with respiratory distress, their condition may worsen, requiring careful observation. This medication should only be administered via slow intravenous infusion, as rapid administration may result in acute symptoms such as phlebitis, vascular pain, nausea, vomiting, and fever. Do not mix with other medications, and avoid administering this drug for a certain period following the administration of blood volume expanders. The infusion solution should be maintained at an appropriate temperature, and any unused solution after opening should be discarded quickly. When administering to neonates and infants under 2 years of age, care should be taken to shield the solution from light to prevent the formation of peroxides and degradation products. Storage should be at room temperature below 25 degrees Celsius, avoiding freezing, and particular care should be taken against exposure to light when used in young children.

Serious side effects

• Severe swelling (edema)
• chest tightness
• shortness of breath
• cyanosis
• hyperlipidemia
• thrombocytopenia
• coma

Mild side effects

• Phlebitis
• vascular pain
• bleeding tendency
• recurrent venous thrombosis
• reticulocytosis
• hypotension
• tachycardia
• rapid breathing
• recurrent shortness of breath
• cyanosis

This medication should be stored in a sealed container to prevent exposure to air and is best kept at room temperature below 25 degrees Celsius to maintain its efficacy and ensure safe use.

Appearance

A milky white emulsion injection in a plastic container for intravenous use.

Package unit

500ml/box × 12